| abstract |
The present invention is provides benzoic acid derivatives and uses thereof. In accordance with one aspect there is provided a compound of formula (I): stereoisomers thereof, or pharmaceutically acceptable salts or hydrates thereof, or physiologically acceptable and hydrolysable esters thereof; wherein: R1 is H, OH, halogen, (C1-C4) alkyl, (C1-C4) alkenyl, (C1-C4) alkoxy, or (C1-C4)alkyl-COO-; R2 is H, OH, halogen, (C1-C4) alkyl, (C1-C4) alkenyl, (C1-C4)alkoxy, or (C1-C4) alkyl-COO-; r3 is H, OH, halogen, (C1-C4) alkyl, (C1-C4) alkenyl, (C1-C4)alkoxy, or (C1-C4) alkyl-COO; R4 is H, OH, halogen, (C1-C4) alkyl, (C1-C4) alkenyl, (C1-C4)alkoxy, or (C1-C4) alkyl-COO-; R5 is H, OH, halogen, (C1-C4) alkyl, (C1-C4) alkenyl, (C1-C4)alkoxy, or (C1-C4) alkyl-COO-; Y is O or -NR', wherein R' is H or (C1-C4) alkyl; n is 0-8; R6 is a 5 to 8 membered lactone or lactam ring; R7 is H, (C1-C4) alkyl, (C1-C4) alkenyl, (C1-C4)alkoxy, phenyl or (C1-C4) alkyl-COO-, wherein the lactam or lactone ring optionally comprises one or more C=C double bonds and the lactam or lactone ring is optionally substituted with one or more (C1-C4)alkyl or (C1-C4) alkenyl groups.The compounds of the present invention are useful for the treatment or prevention of disorders with an etiology associated with or comprising excessive cytokine release. The compounds are also used in the treatment of cancer, inflammatory disorders and disorders associated with an increased stability of mRNA which has an mRNA instability sequence. The present invention further provides processes for preparing benzoic acid derivatives of Formula I. |